Stanford professor James Zou is reportedly raising approximately $100 million for a startup called Human Intelligence, which aims to apply AI to research on the human body. The startup is backed by Nature-published research and FDA-cleared cardiac AI. Zou's research includes an FDA-approved cardiac AI (EchoNet), a Nature-public Virtual Lab that designed novel nanobodies, and a Virtual Biotech multi-agent framework that annotated 56,000 clinical trials. The funding environment for AI drug discovery, which was $11 billion in Q1 2026 alone, is historically accommodating for such a project. The company's name, valuation, and raise amount have not been independently confirmed.